Pharmaceutical Supply Chain – Patent Considerations
July 28, 2022
By: Aziz Burgy, Ross Blau
American Bar Association
Axinn partner Aziz Burgy and associate Ross Blau co-authored "Pharmaceutical Supply Chain – Patent Considerations," a chapter in the third edition of the American Bar Association publication, Pre-ANDA Litigation: Strategies and Tactics for Developing a Drug Product and Patent Portfolio.
Click here to learn more about the publication.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
ABA White Collar Crime Institute 2026
Speaking Engagement
GCR Live Cartels: 2026
Speaking Engagement
Antitrust
Noerr Competition Day 2026
Speaking Engagement
Antitrust
Consumer Brands CPG Legal Forum 2026
Speaking Engagement
NBA CLS 39th Annual Corporate Counsel Conference
Sponsorship
Antitrust
University of Pennsylvania Journal of Business Law Annual Symposium 2026
Speaking Engagement
Antitrust
Axinn Antitrust Insight: District Court Vacates the FTC’s Expansion of HSR Reporting Requirements
Axinn Viewpoints
Antitrust
No More Needles in Haystacks: Congress Requires FDA to Explain Q1/Q2 Sameness
Axinn Viewpoints
Intellectual Property
Oliver Twisted Again: After FDA's Court Losses, Congress Approves FDA's Standards on Orphan Drug Exclusivity
Axinn Viewpoints
Intellectual Property
2025 Healthcare Antitrust Enforcement Wrap Up
Axinn Viewpoints
Antitrust

